Diametric Capital, LP Protalix Bio Therapeutics, Inc. Transaction History
Diametric Capital, LP
- $150 Million
- Q2 2025
A detailed history of Diametric Capital, LP transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, Diametric Capital, LP holds 143,272 shares of PLX stock, worth $346,718. This represents 0.14% of its overall portfolio holdings.
Number of Shares
143,272Holding current value
$346,718% of portfolio
0.14%Shares
1 transactions
Others Institutions Holding PLX
# of Institutions
68Shares Held
8.72MCall Options Held
168KPut Options Held
31.4K-
Jim Simons Renaissance Technologies LLC | New York, Ny1.62MShares$3.91 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.08MShares$2.61 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA826KShares$2 Million0.0% of portfolio
-
Connor, Clark & Lunn Investment Management Ltd.496KShares$1.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA485KShares$1.17 Million0.0% of portfolio
About Protalix BioTherapeutics, Inc.
- Ticker PLX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,753,400
- Market Cap $120M
- Description
- Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...